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Abstract: In this paper, the synthesis of fourteen alkylamino and arylamino 
derivatives of sesquiterpene quinone avarone and its model compound tert-but-
ylquinone is described. Branched, cyclic, allylic and benzylic alkylamino/aryl-
amino groups were introduced into the quinone moiety. For all the obtained 
derivatives, their biological activity and redox properties were studied. The cyto-
toxic activity of the synthesized derivatives towards multidrug resistant (MDR) 
human non-small cell lung carcinoma NCI-H460/R cells, their sensitive counter-
part NCI-H460 and human normal keratinocytes (HaCaT) was investigated. The 
antimicrobial activity towards Gram-positive and Gram-negative bacteria, and 
fungal cultures was determined. Some of the synthesized derivatives showed 
selectivity for cancer cells, including MDR cells. Regarding their cell death ind-
uction potential, the most promising compounds were allylamino derivatives, 
preferentially triggering apoptosis, with high selectivity for cancer cells, inc-
luding MDR cells. Several compounds showed promising antimicrobial activity, 
comparable to those of commercial antibiotic and antimycotic agents.  
Keywords: quinones; anticancer activity; multidrug resistant; apoptosis; anti-
microbial activity; cyclic voltammetry. 
INTRODUCTION 
Cancer is one of the leading causes of death worldwide, with over 8 million 
deaths in 2015.1 Therefore, a great amount of resources and effort have been 
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invested in developing novel strategies and drugs for combating this disease. 
Tackling this serious issue includes various forms of therapies, such as radio-
therapy, chemotherapy, immunotherapy, surgery as well as prevention of cancer 
by reducing the risk of carcinogenesis.2 Chemotherapy involves the application 
of drugs or cocktails of drugs in order to eliminate developed cancer cells. The 
limitations of chemotherapy are low efficacy, lack of selectivity, severe toxicity, 
metastasis and development of drug resistance.3 The phenomenon of multi-drug 
resistance (MDR) is a particular problem, caused by the fast proliferation and 
metabolism of cancer cells together with a proneness to mutations, which enables 
cancer cells to overcome the toxicity of the applied drugs, resulting in resistant 
forms of cancer.4 
Quinones are a class of organic compounds that have a versatile array of act-
ivities, some of which are herbicidal,5 antimalarial,6 antiviral,7 antipsoriatic,8 
antileishmanial9 and cytotoxic activity.10–12 Biological activity of quinones ori-
ginates from dual mode of action. It is a combination of 1,4-Michael addition of 
cellular nucleophiles to conjugate enone system and the generation of reactive 
oxygen species (ROS) in redox cycling reactions of quinone and its hydroquin-
one pair via a semiquinone anion radical.13 Quinone/hydroquinone core-contain-
ing compounds are very abundant in nature, being involved in crucially important 
processes, such as photosynthesis,14 the mitochondrial electron transport chain15 
and protection from oxidizing species.16 Natural products of marine origin are of 
particular interest for their diversity of structures and a myriad of activities, 
together with the vast possibilities for their modifications.17–19 
As a continuation of previous work on alkylamino, aralkylamino and amino 
acid derivatives of avarone and its mimetic tert-butylbenzoquinone (TBQ),20,21 
the synthesis and investigation of the cytotoxic activity of a series of alkylamino 
and aralkylamino derivatives of avarone and tert-butylbenzoquinone on three cell 
lines, i.e., non-small cell lung cancer cells, both the sensitive NCI-H460 and 
multi-drug resistant NCI-H460/R, and healthy human keratinocytes HaCaT are 
reported herein. Since in a previous work, benzylamino derivatives of tert-butyl-
quinone showed good selectivity for tumour cells, including MDR cells, benzyl-
amino derivatives of avarone were synthesized in the present study. Other amines 
selected for derivatization of both quinones were allylamines due to similar elec-
tronic effects of the allyl and benzyl group, and amines leading to sterically more 
compressed derivatives, i.e., sec-butylamine and pyrrolidine. Additionally, their 
antibacterial and antifungal activities were determined. Cyclic voltammetry was 
used to study the redox behaviour of newly synthesized compounds in the system 
quinone–semiquinone–hydroquinone, in order to gain information on the struc-
ture−activity relationship. 
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RESULTS AND DISCUSSION 
Chemistry 
As a continuation of previous work, fourteen aminoquinones 3–10a and  
3–10b were synthesized (preparation of compounds 6a and 6b was presented in a 
previous paper20). Treatment of the parent quinones tert-butylquinone (1) and 
avarone (2) with various amines produced the corresponding two regioisomers of 
aminoquinones via 1,4-Michael addition reactions (Scheme 1).  
 
Scheme 1. Synthesis of the quinone derivatives. 
As expected, with tert-butylquinone, the 2,6-disubstituted quinone products 
were dominant over the 2,5-disubstituted products. On the other hand, with ava-
rone, only in the reaction with pyrrolidine was the 2,6-disubstituted product 
dominant while in the reaction with allylamine, the 2,5-disubstituted product was 
the main product and with the other two nucleophiles, similar amounts of two 
products were obtained. Racemic sec-butylamine was used in the reactions. The 
NMR spectra of the products obtained in its reaction with avarone indicate the 
presence of only one diastereoisomer. Unfortunately, the configuration of the 
asymmetric carbon could not be determined, since all attempts to crystallize the 
products were unsuccessful.  
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Half-wave potentials were recorded at a glassy carbon disk (3 mm diameter) 
in DMSO towards a silver wire immersed in the electrolyte solution containing 
0.01 M silver ions as the reference electrode, and ferrocene as the reference com-
pound. The results are given in Table I and shown in Fig. S-1 of the Supple-
mentary material to this paper.  
TABLE I. Voltammetric half-peak potentials and standard redox potentials of the synthesized 
compounds (V vs. silver/silver chloride electrode) 
Compound Ec1 Ea1 Ec2 Ea2 E01/Fc 
3a –1.210 –1.126 –1.890 –1.741 –1.170 
3b –1.218 –1.154 –1.868 –1.744 –1.186 
4a –1.180 –1.121 –1.812 –1.712 –1.149 
4b –1.210 –1.152 –1.848 –1.733 –1.181 
5a –1.276 –1.214 –1.876 –1.694 –1.244 
5b –1.276 –1.214 –1.865 –1.749 –1.243 
6a20 –1.128 –1.053 –1.800 –1.619 –1.159 
6b20 –1.141 –1.071 –1.803 –1.593 –1.174 
7a –1.193 –1.127 –1.881 –1.774 –1.158 
7b –1.201 –1.133 –1.859 –1.713 –1.168 
8a –1.170 –1.113 –1.830 –1.741 –1.142 
8b –1.177 –1.117 –1.799 –1.689 –1.150 
9a –1.267 –1.163 –1.883 –1.710 –1.217 
9b –1.259 –1.177 –1.861 –1.704 –1.218 
10a –1.115 –1.043 –1.865 –1.733 –1.147 
10b –1.123 –1.054 –1.840 –1.685 –1.157 
Typical quinone electrochemical behaviour was observed for all the synthe-
sized compounds, i.e., two waves that could be attributed to the reduction of qui-
none to the semiquinone radical and, subsequently, to the hydroquinone dianion 
(Fig. S-1). First reduction wave was fully reversible, indicating a diffusion con-
trolled process. However, second reduction process was not reversible, having 
higher peak separation potentials. The derivatization did not perturb the nature of 
these two redox processes, but rather shifted the peak potentials. As expected, all 
the derivatives had more negative reduction potential than the parent quinone. It 
could be assumed that amino substituents with electron-donating ability destabil-
ize the intermediate semiquinone relative to the corresponding quinone. This 
effect leads to a negative shift in the peak potential. Since the inductive effect of 
the alkyl part of the alkylamino substituent influences the electron-donating abil-
ity of the substituent, the pyrrolidino derivatives have the most negative reduct-
ion potentials, while benzylamino and allylamino derivatives have the least nega-
tive one. As previously described,20 the position of the substituent plays a parti-
cular role in shifting the peak potential. It was observed that the 4′-derivatives 
generally had a peak potential more negative by about 10 to 20 mV than the cor-
responding 3′-derivatives. The probable reason is that the arrangement is more 
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favourable when the electron-donating amino and alkyl substituents in semiqui-
none anion radical are both in the meta position to the negative oxygen. 
Anticancer activity 
Derivatives of TBQ were compared with corresponding avarone derivatives 
regarding their growth inhibition activity against human cancer and normal cell 
lines. The cell growth inhibition activity was studied in non-small cell lung car-
cinoma cells – NCI-H460/R, their multidrug resistant (MDR) counterpart – NCI- 
-H460/R and human keratinocytes – HaCaT cells. The differences in response 
between cancer and normal cells, evaluated by the MTT assay after 72 h treat-
ment, are presented in Table II and Fig. S-2 of the Supplementary material. 
TABLE II. Growth inhibition activity (IC50 in µM) of TBQ, avarone and their derivatives in 
human non-small cell lung carcinoma cell lines (NCI-H460 – sensitive and NCI-H460/R – 
MDR variant) and human normal keratinocytes (HaCaT); the IC50 values were calculated 
from a minimum of three independent experiments (average ± standard deviation) 
Compound Cell line NCI-H460 NCI-H460/R HaCaT 
CDDPa 5.2±0.4 1.7±0.1 0.7±0.1 
120a >100 72±8 95±4 
220a,b 84±9 24±4 37±8 
3ab,c 10.5±0.4 16.3±1.3 24.4±1.5 
3bb,c 36.6±1.8 96.3±3.9 72.5±1.5 
4a 9.6±0.1 12.6±0.4 8.5±0.4 
4b 18.3±0.6 21.8±0.2 23.9±0.7 
5ac 40.9±0.4 65.9±2.6 36.8±4 
5bc 44.4±4.0 85.7±2.6 26.8±2.4 
6a20b 14±2 10±2 21±1 
6b20b 19±4 15±2 28±2 
7a 3.5±0.04 3.8±0.1 4±0.1 
7b 37.5±1.1 44.4±0.9 40.6±2 
8a 2.8±0.03 3.0±0.1 3.5±0.1 
8b 18±1.3 24.2±0.7 19.2±0.4 
9a 28.2±3.7 20.4±1.2 19.3±0.8 
9bb 8.9±1.5 7.1±0.2 15.1±0.3 
10ac 54.4±2.2 26.3±2.6 12±1 
10b >100 >100 42.2±3.0 
aSelectivity towards MDR cells (higher efficacy in NCI-H460/R compared to NCI-H460 i.e., IC50 of sensitive 
cancer cells ≥ 1.5 fold than IC50 of corresponding MDR cells); bselectivity towards cancer cells (IC50 of either 
sensitive or MDR cancer cells ≤ 1.5 fold than IC50 of normal cells. The dose response curves are shown in Fig. 
S-2); cresistance (lower efficacy in NCI-H460/R compared to NCI-H460 i.e., IC50 of sensitive cancer cells ≤ 
1.5 fold than IC50 of the corresponding MDR cells) 
The growth inhibition abilities of parent compounds TBQ and avarone, as 
well as CDDP, an FDA-approved drug for non-small cell lung carcinoma treat-
ment,22 were investigated in our previous study.20 CDDP showed stronger effect 
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in MDR cancer cells in comparison with their sensitive counterparts, but it was 
not selective against cancer cells due to the pronounced activity obtained in nor-
mal human keratinocytes. TBQ was largely ineffective in all cell lines while ava-
rone showed high selectivity towards MDR cells. The derivatives had generally a 
higher activity than the parent compounds. Avarone 2,6-disubstituted sec-butyl-
amino and allylamino derivatives (7a and 8a, respectively) exhibited the highest 
activity in all tested cell lines with IC50 values below 5 µM and, importantly, 
their activity was not affected by the presence of MDR phenotype. Corres-
ponding 2,5-disubstituted derivatives 7b and 8b showed the same pattern of acti-
vity (without selectivity against cancer cells) but their efficacy was significantly 
diminished as their IC50 values were around one order of magnitude higher than 
those obtained by 7a and 8a. Similarly, 2,6-disubstituted allylamino derivative 4a 
with IC50 values near 10 µM was more efficient than 4b but without selectivity 
to cancer cells. Benzylamino avarone derivative 10b was the least active com-
pound in all cell lines, while the IC50 values for corresponding 10a and two pyr-
rolidino tert-butylquinone derivatives 5a and 5b were above 25 µM in cancer 
cells. These four derivatives were more active in normal cells. Compounds 3a 
and 9b exhibited both high cytotoxicity and selectivity towards cancer cell lines 
and most notably MDR phenotype did not reduce their activity. Although direct 
correlation between redox properties and cytotoxicity of derivatives with differ-
ent substituents could not be established, it should be noticed that out of two 
regioisomers, the isomer with a less negative cathodic potential of the first wave, 
i.e., the isomer that is more prone to the formation of semiquinone radicals, is 
more active. 
In the tert-butylquinone series, the 6-derivatives were always more active to 
tumour cells than the 5-derivatives. The introduction of the bulky sec-butylamino 
group into the 6-position, i.e., closer to the tert-butyl group, did not have much 
influence on the activity to tumour cells, but it decreased the toxicity to normal 
cells, and hence, contrary to the 6-(butylamino) derivative, the corresponding 
sec-butylamino substituted quinone showed a pronounced selectivity to tumour 
cell lines. This did not apply for a more remote 5 substituent. The introduction of 
allylamino group led to products with higher cytotoxicity than similar derivatives 
with linear saturated alkylamino substituents, but the selectivity for tumour cells 
displayed by 6-(ethylamino) derivative was lost.20 5-(Allylamino) and 5-(benzyl-
amino) products were the only 5-substituted derivatives that showed a relatively 
high cytotoxicity, but only the benzylamino derivative showed selectivity for 
tumour cell lines. The pyrrolidino derivatives were only moderately active, 
without selectivity for tumour cells. If the whole set of compounds is considered, 
for a strong cytotoxic activity against tumour cells, an unsaturated or bulky sub-
stituent should be present in position 6. For achieving selectivity, the set of sub-
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stituents was narrowed to bulky groups, and even more to aralkyl groups (benzyl-
amino, phenethylamino) if selectivity to MDR cells is considered.  
As for avarone derivatives, the 3′-derivatives (2,6-disubstitution) were 
always much more active than the 4′-derivatives (2,5-disubstitution), with the 
exception of the pyrrolidino derivatives when the inverse was true. Within this 
series, the introduction of branching or unsaturation into alkylamino substituent 
increased the cytotoxicity regardless of the position of the substituent. 3′-(sec- 
-Butylamino) and 3′-(allylamino) derivatives showed IC50 values in the range  
3–4 μM. Unfortunately, the selectivity for MDR cells, shown by 3′-(butylamino)-
avarone,20 was lost. The benzylamino derivatives were less active to tumour cells 
than the phenethylamino ones. The 4′-pyrrolidino derivative (the more active 
isomer) showed strong activity to the tumour cell lines, with an IC50 value of 7.1 
μM against the multi-drug resistant cells, and selectivity for tumour cells. The 
3′-derivative showed moderate activity, without selectivity. Summarizing these 
results, the necessary prerequisite for an avarone derivative to have a strong act-
ivity against tumour cells is a substituent with a relatively low number of carbon 
atoms at the position 3′ or pyrrolidine at position 4′. Of these substituents, only 
unbranched saturated butylamino derivative and heterocyclic pyrrolidino derivat-
ive showed the desired selectivity.  
Apoptosis and necrosis are the two main forms of cell death. Apoptosis is 
regarded as a programmed process, with minimal level of ATP required for the 
assembly of a apoptosome complex and activation of caspases, while necrosis is 
often referred to as the complete decay of cell metabolism.23 They can be dis-
tinguished from one another by various morphological and biochemical charac-
teristics, although there is no clear-cut distinction between these two (hence, 
other forms of cell death, i.e., necroptosis, aponecrosis, etc.).24 The most obvious 
characteristics of apoptosis are cell shrinkage, DNA fragmentation, condensation 
of chromatin, formation of apoptotic bodies, disruption of mitochondrial redox 
processes and generation of ATP. Cells undergoing apoptosis do not release their 
constituents into the surrounding tissue because the integrity of the cell mem-
brane is preserved. In addition, macrophages quickly phagocytose apoptotic 
bodies and the surrounding cells do not produce anti-inflammatory cytokines.25 
Therefore, no inflammatory reaction occurs during the apoptotic process. Nec-
rosis, on the other hand, is usually followed by inflammation, because one of the 
main characteristics of necrosis is the loss of membrane integrity and the release 
of the cytoplasmic content into the surrounding area, leading to inflammation.26 
Inflammation, for its part, can damage cells and even cause cancer.27 Bearing 
this in mind, apoptosis is clearly the preferred type of cell death, considering the 
removal of either healthy, aging or tumour cells. Besides inflammation, the other 
characteristics of necrosis are cell swelling and complete abolition of ATP pro-
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duction. However, many types of cancer employ anti-apoptotic mechanisms for 
their survival, so necrosis could be useful in promoting the death of tumour cells. 
The cell death inducing capacity of 25 µM TBQ and the avarone derivatives 
was analyzed after 72 h treatment (Table III, Fig. S-3 of the Supplementary 
material). Both pyrrolidino tert-butylquinone derivatives (5a and 5b) showed sig-
nificant activity towards sensitive cancer cells, triggering both apoptosis and nec-
rosis, which was not observed in normal cells. The allylamino derivatives 4a and 
4b induced apoptotic type of cell death more prominently in both cancer cell 
lines than in HaCaT cells. The sec-butylamino derivatives 3a and 3b also ind-
uced apoptosis, most effectively in NCI-H460 cells. Cells treated with the ava-
rone pyrrolidino derivatives 9a and 9b underwent necrosis as the predominant 
cell death type. Consistent with the cell growth analysis, the inverted efficacy 
pattern of 9a and 9b as well as the selectivity of 9b towards cancer cells was 
confirmed by cell death induction. Compounds 8a and 8b (allylamino derivatives 
of avarone) also predominantly induced necrosis in cancer cells with 8a being the 
significantly more potent derivative. sec-Butylamino derivative 7a was consider-
ably more active against MDR cancer cells in triggering necrotic cell death com-
pared to 7b. A similar but reduced effect was also observed in NCI-H460 and 
HaCaT cells. Importantly, according to the cell death analysis, 7a and 8a were 
shown to be selective against cancer cells. 
TABLE III. Cell death induction by 25 μM TBQ, avarone and their derivatives in human non- 
-small cell lung carcinoma cell lines (NCI-H460 – sensitive and NCI-H460/R – MDR variant) 
and human normal keratinocytes (HaCaT)). CDDP is included as a positive control. The 
values represent percentages of viable, apoptotic and necrotic cells 
Compound Viable cells Early apoptosis Late apoptosis Necrosis AV–PI– AV+PI– AV+PI+ AV–PI+ 
NCI-H460
Control 95.5 2 1.1 1.3 
CDDP 66 1.6 5.2 27.2 
120 95.2 0.5 0.5 3.8 
220 74 3.4 16.3 6.3 
3a 43.8 21.9 28.2 6.1 
3b 85.6 3.5 4.9 6 
4a 5.1 24.9 61.4 8.6 
4b 4.9 23.1 63.9 8.1 
5a 67.4 4.7 11.4 16.5 
5b 51 5.3 18.1 25.6 
7a 53.9 6.6 5.7 33.8 
7b 81.4 0.7 3.9 13.9 
8a 28.6 12.5 18 40.9 
8b 72.1 3.5 7 17.4 
9a 83.6 2 3.5 10.9 
9b 31 3.4 10 55.6 
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TABLE III. Continued 
Compound Viable cells Early apoptosis Late apoptosis Necrosis AV˗PI˗ AV+PI˗ AV+PI+ AV˗PI+ 
NCI-H460/R
Control 95.6 1.6 1.9 0.9 
CDDP 55.3 3.8 13.3 27.6 
120 95.2 0.5 1.2 3.1 
220 65.8 2.6 22.7 8.9 
3a 68.4 9.2 17.5 4.9 
3b 93 2.3 3.2 1.5 
4a 7.3 4.1 64.4 24.2 
4b 11.8 6.3 63.4 18.5 
5a 91.8 2 4.1 2.1 
5b 84.8 2 5.5 7.7 
7a 38.4 3.8 9.8 48 
7b 96.3 1.5 1.4 0.8 
8a 21.7 6.6 19.2 52.5 
8b 55.1 4.4 7.1 33.4 
9a 58.7 5.2 7.7 28.4 
9b 26.9 3.9 10.9 58.3 
HaCaT
Control 93.6 2.9 1 2.4 
CDDP 53.5 1.4 9 36.1 
120 86.8 1.9 3.8 7.5 
220 78.3 2.5 10.1 9.1 
3a 64 14.2 9.7 12.1 
3b 82 6.8 5.5 5.7 
4a 61.5 15.9 8.1 14.5 
4b 33.5 18.8 18.9 28.8 
5a 85.9 4.8 4.9 4.4 
5b 85.3 4.9 4 5.8 
7a 72.3 1.1 1 25.6 
7b 95.7 0.5 0.6 3.2 
8a 73.8 2.4 4.1 19.7 
8b 89.3 0.6 0.8 9.3 
9a 97.2 0.3 0.3 2.2 
9b 83.7 0.9 1.1 14.3 
The cell death-inducing activity of compounds 4a and 4b significantly stand 
out from the others in the series. The majority of the cells treated with 4a or 4b 
underwent apoptotic cell death, targeting late apoptosis preferentially. Most imp-
ortantly, this pair were very selective toward cancer cell lines, both sensitive and 
resistant ones, particularly the 4a derivative with over 60 % of viable cells in 
healthy HaCaT cell lines. This distinction could be attributed to the allyl moiety. 
The probable reason is the additional generation of ROS via allyl radicals, 
formed by the decomposition of the semiquinone radical generated by the one-
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electron reduction of allylamino quinone (the other product would be amino qui-
none) and/or the formation of cytotoxic acrolein by the oxidative metabolism of 
allylamino quinones.28 Considering that allylamino TBQ derivatives preferen-
tially induce (late) apoptosis, and that cancer cells are usually already in a state of 
oxidative stress,29 this seems a plausible explanation for the selective action.  
Antimicrobial activity 
Compounds 3–10a and 3–10b were tested for their antimicrobial activity 
against Gram-positive and Gram-negative bacteria, as well as fungal strains, and 
compared to the commercial antibiotics amikacin and antimycotic nystatin. The 
results are given in Tables IV and V.  
Most of the derivatives showed weak activity in comparison to amikacin, 
having at least an order of a magnitude higher MIC. The most active TBQ deri-
vatives were allylamino derivatives 4a and 4b, with activity comparable to ami-
kacin for E. coli. 
This pair had almost identical MIC for all strains except M. luteus (ATCC 
10240 and 4698) and S. enterica. The pair 3a and 3b showed generally weaker 
activity than 4a and 4b, with 3a being only slightly more active against B. 
subtilis, M. luteus (ATCC 10240 and 4698) and E. coli, and 3b for K. rhizophila. 
The pair 5a and 5b displayed the weakest activity of all the tested TBQ 
compounds, with some activity only towards K. rhizophila, E. coli and M. luteus, 
ATCC 4698, (only 5a). The avarone counterparts showed no activity, as expected 
from previous results.20 The probable reason for inactivity is insufficient hydro-
philicity. This conclusion is corroborated by the fact that several amino acid deri-
vatives of avarone showed strong antibacterial activity.21 In general, in order to 
show a relatively broad activity comparable to amikacin, tert-butylquinone deri-
vatives should have a non-branched medium length alkylamino group or an aral-
kyl group in position 3′. It is interesting that among the avarone amino acid deri-
vatives, the most active were those with aromatic amino acids, implying that 
there is an aromatic binding site in a putative target. All the tested compounds, 
except 10a and 10b, showed stronger activity toward C. albicans than nystatin, 
with 3a, 4a, 4b and 5a even having a two orders of a magnitude lower MIC (less 
than 50 μM). Towards A. brasiliensis, the activities were generally comparable to 
that of nystatin, with 4a, 4b and 5a displaying stronger activity. Considering S. 
cerevisiae, 4a, 5a, 7b, 9a and 9b possess stronger activity than amikacin. Of all 
the tested compounds, 4a showed the strongest antifungal activity, while 10a and 
10b showed no activity at all. Based on these results and those from a previous 
paper,20 it could be concluded that in order to achieve a strong anti-Candida 
activity, a compound should be a 6-substituted 2-tert-butyl-1,4-benzoquinone 
(exception are allylamino derivatives, where both isomers have a similar activity),  
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with at least three carbon atoms in the side chain. The avarone derivatives were 
much less active, but in contrast to antibacterial effects, most of them had some 
activity, although much lower than the amino acid derivatives.21 The amino acid 
derivatives of TBQ had weak antimicrobial activity, probably due to their 
excessive hydrophilicity. 
TABLE V. Antifungal in vitro activity (MIC/mM) 
Compound 
Fungi 
Candida albicans  
(ATCC 10231) 
Aspergillus brasiliensis 
(ATCC 16404) 
Saccharomyces cerevisiae 
(ATCC 9763) 
3a 0.042 1.33 1.33 
3b 0.166 2.656 2.656 
4a 0.047 0.36 0.36 
4b 0.047 0.716 1.427 
5a 0.042 0.339 0.673 
5b 0.673 2.679 2.679 
*6a 2.333 2.333 2.333 
6b20 – – – 
7a 0.41 1.631 0.817 
7b 0.41 1.631 1.631 
8a 0.852 1.701 3.401 
8b 1.701 1.701 3.401 
9a 1.638 1.638 0.82 
9b 1.638 1.638 0.411 
10a – – – 
10b – – – 
Nystatin 2.7 1.35 1.35 
EXPERIMENTAL 
General synthetic procedure 
The parent quinones were obtained from hydroquinones according to a previously des-
cribed procedure.20 Quinones (300mg; 1.83 mmol 1; 0.96 mmol 2) were dissolved in ethanol 
(50 mL). Amine hydrochloride salts (in large excess, 22×) were prepared as aqueous solut-
ions. The pH of the solution was adjusted to 7–8 by the addition of solid sodium bicarbonate, 
and the solution was added to quinone. Water and ethanol were added to the reaction mixture 
to a final ratio water:ethanol of 1:1, and total volume of 300 mL. The reaction mixture was 
stirred at 60–70 °C for 3 h. Ethanol was removed by vacuum evaporation, and the reaction 
mixture was extracted two times by dichloromethane, with half the volume of the aqueous 
phase each time. The organic phase was separated, dried with anhydrous calcium chloride, 
and the solvent was removed by evaporation under vacuum. The crude products were separ-
ated by column or low-bar chromatography and purified by preparative thin-layer chromato-
graphy, with the indicated solvents. Numbering scheme for assignment of signals in NMR 
spectra of all compounds is given in Scheme S-1. 
Cyclic voltammetry 
Electrochemical behaviour of synthesized aminoquinones was studied as previously des-
cribed.20 
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Biological activity 
Cytotoxic, antibacterial and antifungal activity of synthesized compounds were analyzed 
according to a previous study.20 
CONCLUSIONS 
Among the 14 newly synthesized compounds, a potential to be antitumor 
agents was shown for sec-butylamino derivatives of tert-butylquinone (3a and b) 
because of their selectivity for tumour cells, allylamino derivatives of tert-butyl-
quinone (4a and b) because of their selective induction of apoptosis in tumour 
cells, including MDR cells, 3′-(sec-butylamino)avarone (7a) and 3′-(allylamino)-
avarone (8a) because of their higher cytotoxic activity than cisplatin, as well as 
4′-pyrrolidinoavarone (9b) because of selectivity to tumour cells, including MDR 
cells. Some derivatives showed promising antimicrobial properties: sec-butyl-
amino (3a) and allylamino (4a and b) derivatives of tert-butylquinone, because 
of an activity against E. coli similar to that of amikacin, and strong antifungal 
activity to C. albicans, which also applies to the pyrrolidino derivative of tert- 
-butylquinone (5a).  
SUPPLEMENTARY MATERIAL 
Additional experimental results, as well as spectroscopic and analytical data, are avail-
able electronically on the pages of the journal’s website: http://www.shd.org.rs/JSCS/, or from 
the corresponding author on request. 
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И З В О Д  
АЛКИЛАМИНО И АРАЛКИЛАМИНО ДЕРИВАТИ АВАРОНА И ЊЕГОВОГ МИМЕТИКА 
КАО СЕЛЕКТИВНИ АГЕНСИ ПРЕМА ЋЕЛИЈАМА НЕСИТНОЋЕЛИЈСКОГ КАРЦИНОМА 
ПЛУЋА, ЊИХОВ АНТИБАКТЕРИЈСКИ И АНТИФУНГАЛНИ ПОТЕНЦИЈАЛ 
MАРКО ЈЕРЕМИЋ1, JЕЛЕНА ДИНИЋ2, MИЛИЦА ПЕШИЋ2, MАРИЈА СТЕПАНОВИЋ2, ИРЕНА НОВАКОВИЋ3, 
ДЕЈАН ШЕГАН4 и ДУШАН СЛАДИЋ4 
1Иновациони центар Хемијског факултета, Универзитет у Београду, Студентски трг 12–16, 11000 
Београд, 2Институт за биолошка истраживања „Синиша Станковић“, Универзитет у Београду, 
Деспота Стефана 142, 11060 Београд, 3Институт за хемију, технологију и металургију, 
Универзитет у Београду, Центар за хемију, Његошева 12, 11000 Београд и 4Хемијски факултет, 
Универзитет у Београду, Студентски трг 12–16, 11000 Београд 
У овом раду, описана је синтеза четрнаест алкиламино и аралкиламино деривата 
сесквитерпенског хинона аварона и његовог модел-једињења, терц-бутилхинона. Алкил-
амино/аралкиламино групе које су уведене у хинонски остатак биле су разграната, цик-
лична, алилна и бензилна. За све добијене деривате одређена је биолошка активност и 
редокс особине. Испитана је цитотоксична активност синтетисаних деривата према 
резистентним ћелијама неситноћелијског карцинома плућа (NCI-H460/R), њиховом 
осетљивом пандану (NCI-H460) и нормалним хуманим кератиноцитима (HaCaT). Одре-
ђена је и антимикробна активност према Грам-позитивним и Грам-негативним бакте-
ријама и културама гљивица. Неки од синтетисаних деривата су показали селективност 
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према ћелијама канцера, укључујући и резистентне ћелије. Што се тиче потенцијала за 
индукцију ћелијске смрти, деривати који највише обећавају су алиламино деривати, 
који преференцијално активирају апоптозу, са великом селективношћу према ћелијама 
канцера, укључујући и резистентне ћелије. Неколико једињења је показало обећавајућу 
антимикробну активност, упоредиву са комерцијалним антибиотицима и антимико-
тицима.  
(Примљено, 27. јуна, прихваћено 23. јула 2018) 
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